178 related articles for article (PubMed ID: 31023104)
1. A patent review of bisphosphonates in treating bone disease.
Holstein SA
Expert Opin Ther Pat; 2019 May; 29(5):315-325. PubMed ID: 31023104
[TBL] [Abstract][Full Text] [Related]
2. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
Wasko BM; Dudakovic A; Hohl RJ
J Pharmacol Exp Ther; 2011 May; 337(2):540-6. PubMed ID: 21335425
[TBL] [Abstract][Full Text] [Related]
4. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells.
Das S; Edwards PA; Crockett JC; Rogers MJ
Biochim Biophys Acta; 2014 Apr; 1841(4):569-73. PubMed ID: 24369118
[TBL] [Abstract][Full Text] [Related]
6. Geranylgeranyl diphosphate synthase: an emerging therapeutic target.
Wiemer AJ; Wiemer DF; Hohl RJ
Clin Pharmacol Ther; 2011 Dec; 90(6):804-12. PubMed ID: 22048229
[TBL] [Abstract][Full Text] [Related]
7. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.
Haney SL; Wills VS; Wiemer DF; Holstein SA
Molecules; 2017 May; 22(6):. PubMed ID: 28555000
[TBL] [Abstract][Full Text] [Related]
9. The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates.
Ling Y; Li ZH; Miranda K; Oldfield E; Moreno SN
J Biol Chem; 2007 Oct; 282(42):30804-16. PubMed ID: 17724033
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
Dunford JE
Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
[TBL] [Abstract][Full Text] [Related]
11. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Thompson K; Dunford JE; Ebetino FH; Rogers MJ
Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
15. Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010).
Sun S; McKenna CE
Expert Opin Ther Pat; 2011 Sep; 21(9):1433-51. PubMed ID: 21702715
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
Ebetino FH; Sun S; Cherian P; Roshandel S; Neighbors JD; Hu E; Dunford JE; Sedghizadeh PP; McKenna CE; Srinivasan V; Boeckman RK; Russell RGG
Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
Drake MT; Cremers SC
Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
19. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
20. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Lawson MA; Coulton L; Ebetino FH; Vanderkerken K; Croucher PI
Biochem Biophys Res Commun; 2008 Dec; 377(2):453-457. PubMed ID: 18929536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
